Evidence check: Pharmakogenetik Medicheck in the context of Langlebigkeit

The Pharmakogenetik Medicheck from MyBody-X is marketed in the context of longevity, but the evidence for this use is weak. Pharmacogenetics examines how genetic variants (e.g., in CYP2C19, CYP2D6) affect drug metabolism – clinically useful for dose adjustment, but not for predicting lifespan. Longevity is multifactorial: diet, exercise, environment, and chance play far larger roles than single drug-metabolism genes. The test provides no personalized longevity recommendations, only risk indications for drug metabolism. Moreover, in Germany it falls under the Genetic Diagnostics Act (GenDG) and is labeled as a lifestyle test, not medical diagnostics. Its relevance for 'longevity' is therefore misleading. Those aiming to optimize lifespan should rely on validated biomarkers (blood values, microbiome) and evidence-based lifestyle interventions – not a pharmacogenetic test.